Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T16:57:49.793Z Has data issue: false hasContentIssue false
  • English
  • Français

L-tryptophan and the eosinophilia-myalgia syndrome

Drugs and Therapeutics Bulletin (1990), 28, 37–38

Published online by Cambridge University Press:  02 January 2018

Philip J. Cowen
Philip J. Cowen*
Affiliation:
MRC Unit of Clinical Pharmacology and University Department of Psychiatry, Littlemore Hospital, Oxford OX4 4XN
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Eosinophilia-myalgia syndrome (EMS) is an alarming illness, occasionally fatal, which is characterised by severe myalgia, arthralgia, fatigue and, it now appears, ingestion of L-tryptophan (Hertzman et al, 1990). At first sight this appears rather surprising because tryptophan is, of course, present in the normal diet, albeit in smaller quantities (about 750 mg daily), than that usually prescribed for the treatment of depression (about 3 g daily). Furthermore, L-tryptophan has been available in the UK for the treatment of depression for over 20 years without previous cases of EMS coming to light, despite the dramatic nature of the symptomatology. All this suggests that a contaminant in the preparation of synthetic L-tryptophan could be responsible for the development of EMS, a view strengthened by the resemblance of EMS to the toxic oil syndrome which was caused by contaminated olive oil.

Type
Expert Opinion
Information
Psychiatric Bulletin , Volume 14 , Issue 12 , December 1990 , pp. 738 - 739
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1990

References

Barker, W. A., Scott, J. & Ecclestone, D. (1990) The Newcastle chronic depression study: results of a treatment regime. International Clinical Psychopharmacology, 2, 261–272.CrossRefGoogle Scholar
Committee on Safety of Medicines (1990) Withdrawal of Pacitron and Optimax. 12 April 1990.Google Scholar
Coppen, A., Shaw, D. M. & Farrell, J. P. (1963) Potentiation of the antidepressive effect of a monoamine oxidase inhibitor. Lancet, i, 79–80.CrossRefGoogle Scholar
Ferrier, I. N., Ecclestone, D., Moore, P. M. & Wood, K. A. (1990) Relapse of chronic depressives on withdrawal of L-tryptophan. Lancet, 336, 380–381.CrossRefGoogle ScholarPubMed
Hale, A. SA., Proctor, A. W. & Bridges, P. K. (1987) Clomipramine, tryptophan and lithium in combination for resistant endogenous depression: seven case studies. British Journal of Psychiatry, 143, 213–217.CrossRefGoogle Scholar
Hertzman, P. A., Blevins, W. L., Mayer, J., Greenfield, B., Ting, M. & Gleich, G. J. (1990) Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. New England Journal of Medicine, 322, 869–873.CrossRefGoogle ScholarPubMed
Slutsker, L., Hoesly, F. C., Miller, L., Williams, L. P., Watson, J. C. & Fleming, D. W. (1990) Eosinophiliamyalgia syndrome associated with exposure to tryptophan from a single manufacturer. Journal of the American Medical Association, 264, 213–217.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.